Collateral damage from targeted therapy

  title={Collateral damage from targeted therapy},
  author={Wayne A. Rankin and Penelope Coates},
The introduction of biological therapies using monoclonal antibodies and small-molecule inhibitors targeted against cell surface receptors and associated signalling molecules has led to marked changes in the management of inflammatory and malignant disease. Theoretically, the use of such agents in oncology provide therapeutic benefit without the systemic toxicities associated with cytotoxic chemotherapies. In practice, however, many of these agents have marked toxicities, some able to be… CONTINUE READING

Similar Papers